Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16429399 | 0.88 | LPL (0.40) | LPLLIPGSNCAEGFRPRMT5 | |
| SCHEMBL3262215 | 0.80 | PRMT5 (0.47) | LPLLIPGSNCAEGFRPRMT5 | |
| SCHEMBL874992 | 0.75 | MMP12 (0.45) | LPLLIPGSNCAEGFR | |
| SCHEMBL29525463 | 0.75 | MMP12 (0.45) | LPLLIPGSNCAEGFR | |
| SCHEMBL15574354 | 0.74 | ALDH1A1 (0.49) | LPLLIPGSNCAIDO1TDO2 | |
| SCHEMBL3831957 | 0.73 | PLAU (0.47) | LPLLIPGSNCAEGFRIDO1 | |
| SCHEMBL15296449 | 0.73 | EGFR (0.40) | LPLLIPGSNCAEGFRIDO1 | |
| SCHEMBL25431172 | 0.72 | GSK3A (0.42) | LPLLIPGEGFRCA1CA2 | |
| SCHEMBL1318307 | 0.72 | MAPT (0.45) | LPLLIPGIDO1 | |
| SCHEMBL29741038 | 0.72 | MAPT (0.45) | LPLLIPGIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348454-A1 | COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| EP-3704121-B1 | DIAZASPIRO ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-12-21 | — | — | EP | disclosed |
| US-11192891-B2 | Diazaspiro ROCK inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210188848-A1 | DIAZASPIRO ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-24 | — | — | US | disclosed |
| EP-3704121-A1 | DIAZASPIRO ROCK INHIBITORS | Bristol-Myers Squibb Company (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-2616443-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | Exelixis, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192891-B2 | Diazaspiro ROCK inhibitors | ROCK1, MYLK, ROCK2 | LPL 4478/4885LIPG 1119/4885SNCA 1435/4885 |
| US-20130165440-A1 | JAK1 Inhibitors | JAK1, JAK2, JAK3 | LPL 4337/4885LIPG 4175/4885SNCA 2105/4885 |
| US-20230348454-A1 | COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | BPGM, PGAM1, HBG1 | LPL 1511/4885LIPG 213/4885SNCA 1302/4885 |
| US-20210188848-A1 | DIAZASPIRO ROCK INHIBITORS | ROCK1, MYLK, ROCK2 | LPL 4478/4885LIPG 1119/4885SNCA 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.